| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 |
| filingDate |
2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5c0b9859714ea7c706a984d5fbc6cd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_482cfc4973b714b4874ecd3ee25fd164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e30c4a84610a725ebe317dfacbb52ea1 |
| publicationDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021047573-A1 |
| titleOfInvention |
Use of mek inhibitor in combination with cdk4/6 inhibitor in preparation of drugs for treating tumors |
| abstract |
Disclosed is the use of an MEK inhibitor in combination with a CDK4/6 inhibitor in the preparation of drugs for treating tumors. Specifically, the MEK inhibitor is selected from a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the CDK4/6 inhibitor is selected from a compound as shown in formula (II) or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2019-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |